The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.
IMI is the world’s biggest public-private partnership and it facilitates collaboration between the key players involved in healthcare research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. The projects will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments.
Greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation. The research and innovation efforts will also open new commercial possibilities based on new services and products. The research, industry and societal sectors involved in IMI2 will benefit from the cooperation and knowledge sharing which take place in these projects.
